Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy
Clinical trial NCT01723072 · COMPLETED
Trial details
- NCT number
- NCT01723072
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-01-23
- Primary completion
- 2014-05-09
- Enrollment
- 91
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.